Immunotrex has developed several novel therapeutic agents/compounds for the treatment of sepsis, referred to as “KDEON™”. These are novel small peptides (11 or 12 amino acids long) created by rational design aimed at neutralizing the injurious effects of endotoxin, thereby capable of blocking the multiple pathophysiologic processes involved in sepsis.
According to an August 2013 study conducted by the Agency for Healthcare Research and Quality, a division of the United States Department of Health and Human Services (HHS):
Sepsis is the most expensive condition treated in hospitals.
Annual costs to the U.S healthcare system exceed $20 billion.
Sepsis accounted for 5.2% of the national costs for hospitalization in 2011.
Sepsis was also the most expensive condition billed to Medicare (6.9%).
Due to the proprietary nature of these molecules, Immunotrex will be happy to provide more details about these peptides, including their structures, after a confidentiality agreement is executed.